Drug intelligence / Profile preview

HD003

Development stage: Phase 2
Lead developer: Huadao Biomedical

Overview

HD003 is a biological product developed by Huadao (Shanghai) Biomedical Co., Ltd. It is currently in Phase 1/2 clinical development for the treatment of Multiple Myeloma and Relapse multiple myeloma. The specific mechanism of action has not been publicly detailed.

Other names: BCMA-targeted HD003 CAR-T cells

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on HD003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD003.